The story
Founded by Richard A. Friesner and William Andrew Goddard III in 1990.1
SDGR on Nasdaq
Schrödinger
Logo: schrodinger.com5
American life sciences company
Schrödinger, Inc. is an international scientific software and biotechnology company that specializes in developing computational tools and software for drug discovery and materials science. Schrödinger's software is used by pharmaceutical companies, biotech, tech, chemicals, energy, aerospace firms, and academic researchers to simulate and model the behavior of molecules at the atomic level. This accelerates the design and develops new drugs and materials more efficiently, reducing the time and cost of bringing them to market.3 It was founded by Richard A. Friesner and William Andrew Goddard III.1 Its shares trade on Nasdaq under the symbol SDGR.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Arvinas (United States), LIGAND PHARMACEUTICALS INC or Keros Therapeutics, Inc., or pick any stock.
- TickerSDGR on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersNew York City1
- Websitewww.schrodinger.com
- Incorporated inDE7
- Business address1540 Broadway, 24Th Floor, New York, Ny 100367
- Filer categoryLarge accelerated filer7
- Legal formCorporation4
- LEI984500044BAE4791E5594
- StatusActive4
- LEI statusIssued and current4
- Registered addressCORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States4
- Registered withDivision of Corporations, Department of State, 25092134
See how the biggest companies compare on our leaderboards
Schrödinger, Inc. is an international scientific software and biotechnology company that specializes in developing computational tools and software for drug discovery and materials science.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
55.7%Gross margin6
-65.2%Operating margin6
-40.4%Net margin6
23.3%Revenue growth, 20256
-28.4%Return on equity6
$12.5MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Software Products And Services brought in 59% of the revenue Schrödinger broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Software Products And Services | $159.1M | $180.4M | $199.5M |
| Drug Discovery | $57.5M | $27.2M | $56.4M |
| Hosted Software | $20.4M | $35.3M | $45.1M |
| Maintenance | $23.1M | $23.3M | $27.3M |
| Professional Services | $9.4M | $9.8M | $9.6M |
Business segments
Software brought in 78% of the revenue Schrödinger broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Software | $159.1M | $180.4M | $199.5M |
| Drug Discovery | $57.5M | $27.2M | $56.4M |
Regions
United States brought in 60% of the revenue Schrödinger broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $162.0M | $114.9M | $153.0M |
| EMEA | $29.1M | $65.7M | $75.2M |
| APAC | $24.6M | $25.8M | $26.2M |
| Rest of the world | $1.0M | $1.2M | $1.6M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue39¢$113.3M
- Research and development60¢$173.1M
- Income tax0¢$939.0K
Out of $255.9M in revenue.6 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending10¢$1.4M
- Kept or used elsewhere90¢$12.5M
Out of $13.9M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $255.9M | $207.5M | $216.7M |
| Total cost of revenues | $113.3M | $75.5M | $76.0M |
| Gross profit | $142.6M | $132.1M | $140.7M |
| Research and development | $173.1M | $201.8M | $181.8M |
| Sales and marketing | $41.0M | $39.9M | $37.2M |
| General and administrative | $95.4M | $99.7M | $99.1M |
| Total operating expenses | $309.5M | $341.4M | $318.1M |
| Loss from operations | -$166.9M | -$209.3M | -$177.4M |
| Gain on equity investments | $0 | $0 | $147.2M |
| Change in fair value of equity investments | $48.2M | $5.7M | $53.5M |
| Other income | $16.4M | $17.9M | $19.7M |
| Total other income | $64.6M | $23.6M | $220.4M |
| (Loss) income before income taxes | -$102.3M | -$185.7M | $42.9M |
| Income tax expense | $939.0K | $1.4M | $2.2M |
| Net (loss) income | -$103.3M | -$187.1M | $40.7M |
| Net (loss) income per share attributable to common and limited common stockholders, basic (in USD per share) | -$1.41 | -$2.57 | $0.57 |
| Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic (in shares) | 73.4M shares | 72.7M shares | 71.8M shares |
| Net (loss) income per share of common and limited common stockholders, diluted (in USD per share) | -$1.41 | -$2.57 | $0.54 |
| Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares) | 73.4M shares | 72.7M shares | 75.0M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $230.5M | $147.3M | ||
| Restricted cash | $6.9M | $15.3M | ||
| Marketable securities | $164.9M | $204.8M | ||
| Accounts receivable, net of allowance for doubtful accounts of $440 and $210 | $83.0M | $235.7M | ||
| Unbilled and other receivables, net of allowance for unbilled receivables of $140 and $100 | $21.4M | $19.6M | ||
| Prepaid expenses | $12.5M | $12.2M | ||
| Total current assets | $519.3M | $635.0M | ||
| Property and equipment, net | $19.5M | $24.2M | ||
| Equity investments | $73.6M | $43.2M | ||
| Goodwill | $4.8M | $4.8M | ||
| Right of use assets - operating leases | $102.7M | $111.9M | ||
| Other assets | $6.3M | $4.2M | ||
| Total assets | $726.2M | $823.2M | ||
| Accounts payable | $11.5M | $10.7M | ||
| Accrued payroll, taxes, and benefits | $39.3M | $42.1M | ||
| Deferred revenue | $112.9M | $111.9M | ||
| Lease liabilities - operating leases | $16.4M | $16.8M | ||
| Other accrued liabilities | $9.2M | $10.3M | ||
| Total current liabilities | $189.1M | $191.7M | ||
| Deferred revenue, long-term | $78.9M | $108.8M | ||
| Lease liabilities - operating leases, long-term | $92.8M | $101.1M | ||
| Other liabilities, long-term | $1.3M | $146.0K | ||
| Total liabilities | $362.1M | $401.8M | ||
| Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | ||
| Additional paid-in capital | $992.0M | $946.0M | ||
| Accumulated deficit | -$628.8M | -$525.5M | ||
| Accumulated other comprehensive income | $107.0K | $220.0K | ||
| Total stockholders' equity | $364.1M | $421.4M | $548.6M | $447.9M |
| Total liabilities and stockholders' equity | $726.2M | $823.2M | ||
| Allowance for doubtful accounts receivable | $440.0K | $210.0K | ||
| Allowance for unbilled receivable | $140.0K | $100.0K | ||
| Preferred stock, par value (in USD per share) | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $230.5M | $147.3M | ||
| Restricted cash | $6.9M | $15.3M | ||
| Marketable securities | $164.9M | $204.8M | ||
| Accounts receivable, net of allowance for doubtful accounts of $440 and $210 | $83.0M | $235.7M | ||
| Unbilled and other receivables, net of allowance for unbilled receivables of $140 and $100 | $21.4M | $19.6M | ||
| Prepaid expenses | $12.5M | $12.2M | ||
| Total current assets | $519.3M | $635.0M | ||
| Property and equipment, net | $19.5M | $24.2M | ||
| Equity investments | $73.6M | $43.2M | ||
| Goodwill | $4.8M | $4.8M | ||
| Right of use assets - operating leases | $102.7M | $111.9M | ||
| Other assets | $6.3M | $4.2M | ||
| Total assets | $726.2M | $823.2M | ||
| Accounts payable | $11.5M | $10.7M | ||
| Accrued payroll, taxes, and benefits | $39.3M | $42.1M | ||
| Deferred revenue | $112.9M | $111.9M | ||
| Lease liabilities - operating leases | $16.4M | $16.8M | ||
| Other accrued liabilities | $9.2M | $10.3M | ||
| Total current liabilities | $189.1M | $191.7M | ||
| Deferred revenue, long-term | $78.9M | $108.8M | ||
| Lease liabilities - operating leases, long-term | $92.8M | $101.1M | ||
| Other liabilities, long-term | $1.3M | $146.0K | ||
| Total liabilities | $362.1M | $401.8M | ||
| Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | ||
| Additional paid-in capital | $992.0M | $946.0M | ||
| Accumulated deficit | -$628.8M | -$525.5M | ||
| Accumulated other comprehensive income | $107.0K | $220.0K | ||
| Total stockholders' equity | $364.1M | $421.4M | $548.6M | $447.9M |
| Total liabilities and stockholders' equity | $726.2M | $823.2M | ||
| Allowance for doubtful accounts receivable | $440.0K | $210.0K | ||
| Allowance for unbilled receivable | $140.0K | $100.0K | ||
| Preferred stock, par value (in USD per share) | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net (loss) income | -$103.3M | -$187.1M | $40.7M |
| Gain on equity investments | $0 | $0 | -$147.2M |
| Changes in fair value of equity investments | -$48.2M | -$5.7M | -$53.5M |
| Depreciation and amortization | $6.0M | $6.2M | $5.6M |
| Stock-based compensation | $43.0M | $49.9M | $47.8M |
| Noncash investment accretion | -$1.9M | -$7.6M | -$7.8M |
| Loss on disposal of property and equipment | $20.0K | $8.0K | $142.0K |
| Accounts receivable, net | $152.7M | -$169.7M | -$10.0M |
| Unbilled and other receivables | -$1.7M | $3.5M | -$10.0M |
| Reduction in the carrying amount of right of use assets - operating leases | $9.1M | $8.9M | $7.8M |
| Prepaid expenses and other assets | -$2.4M | -$3.5M | -$8.5M |
| Accounts payable | $908.0K | -$6.1M | $7.3M |
| Accrued payroll, taxes, and benefits | -$2.8M | $10.3M | $6.9M |
| Deferred revenue | -$29.0M | $155.5M | -$18.3M |
| Lease liabilities - operating leases | -$8.6M | -$10.1M | -$3.7M |
| Other accrued liabilities | $91.0K | -$1.9M | $5.9M |
| Net cash provided by (used in) operating activities | $13.9M | -$157.4M | -$136.7M |
| Purchases of property and equipment | -$1.4M | -$7.3M | -$13.4M |
| Purchases of equity investments | $0 | -$3.1M | -$4.1M |
| Distribution from equity investment | $0 | $0 | $147.2M |
| Proceeds from sale and disposition of equity investments | $17.7M | $48.8M | $0 |
| Purchases of marketable securities | -$313.0M | -$251.3M | -$320.6M |
| Proceeds from maturity of marketable securities | $354.6M | $361.8M | $384.0M |
| Net cash provided by investing activities | $57.9M | $148.8M | $193.0M |
| Proceeds from issuances of common stock upon stock option exercises | $3.0M | $1.5M | $9.4M |
| Proceeds from issuance of common stock in ATM offering | $0 | $8.9M | $0 |
| Payment of offering costs | $0 | -$177.0K | -$373.0K |
| Principal payments on finance leases | -$58.0K | -$58.0K | -$19.0K |
| Net cash provided by financing activities | $2.9M | $10.1M | $9.0M |
| Net increase in cash and cash equivalents and restricted cash | $74.7M | $1.6M | $65.3M |
| Purchases of property and equipment in accounts payable | $40.0K | $162.0K | $192.0K |
| Purchases of property and equipment in accrued liabilities | $81.0K | $157.0K | $457.0K |
| Acquisition of right of use assets - operating leases, contingency resolution | $0 | $2.8M | $514.0K |
| Acquisition of right of use assets in exchange for lease liabilities - operating leases | $0 | $0 | $15.1M |
| Acquisition of right of use assets in exchange for lease liabilities - finance leases | $0 | $0 | $279.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Schrödinger sits at the top of its group. 5 entities, 5 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Schrödinger
- Rubric Capital Management LP Filed SCHEDULE 13G/A on Schrödinger, latest May 15, 2026 (4 filings since Nov 13, 2024)
- Sumitomo Mitsui Trust Group Filed SCHEDULE 13G/A on Schrödinger, latest Apr 30, 2026 (3 filings since Feb 4, 2025)
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on Schrödinger, latest Apr 29, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Schrödinger, latest Mar 27, 2026 (5 filings since Feb 10, 2022)
- BlackRock Filed SCHEDULE 13G/A on Schrödinger, latest Jul 18, 2025 (6 filings since Feb 4, 2022)
- ARK Investment Management LLC Filed SC 13G on Schrödinger, latest Feb 10, 2023
- David E. Shaw Filed SC 13G/A on Schrödinger, latest Dec 1, 2021
- Schrödinger Wilmington, Delaware, United States
- Reo Discovery Limited Subsidiary · Ireland
- Schrodinger Korea LLC Subsidiary · South Korea
- Schrödinger India Private Limited Subsidiary · India
- Schrödinger Technologies Ltd Subsidiary · United Kingdom
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Schrödinger reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated depreciation | $25.0M6 Dec 31, 2025 | $20.9M6 Dec 31, 2024 | +19.9% |
| Operating-lease assets (leased space) | $102.7M6 Dec 31, 2025 | $111.9M6 Dec 31, 2024 | −8.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $230.5M6 Dec 31, 2025 | $147.3M6 Dec 31, 2024 | +56.5% |
| Marketable securities, current | $164.9M6 Dec 31, 2025 | $204.8M6 Dec 31, 2024 | −19.5% |
| Debt securities available for sale | $164.9M6 Dec 31, 2025 | $204.8M6 Dec 31, 2024 | −19.5% |
| Stakes in other companies (equity method) | $73.6M6 Dec 31, 2025 | $43.2M6 Dec 31, 2024 | +70.4% |
Intangibles and goodwill
Properties, in its own words
Our principal facilities consist of office space. We occupy approximately 136,047 square feet of office space in New York, New York under a lease that currently expires in December 2037, 35,000 square feet of office space in Portland, Oregon under a lease that currently expires in September 2026, and 48,987 square feet of office space in Hyderabad, India under a lease that currently expires in April 2028. Additionally, we lease office space at our other office locations around the world. We believe our facilities are adequate and suitable for our current needs and that should it be needed, suitable additional or alternative space will be available to accommodate our operations.
Item 2 of the 10-K filed Feb 25, 2026.19
Leadership
Who has led Schrödinger, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
1995200020052010201520202025
- FounderRichard A. Friesner1
- FounderWilliam Andrew Goddard III1
- Chief executive officerRamy Farid Mar 2, 2021 to now20
- PresidentKaren Akinsanya Feb 10, 2023 to now21
- PresidentRamy Farid Mar 2, 2021 to Feb 10, 202320
- Chief financial officerRachit Jain May 22, 2025 to now22
- Chief financial officerGeoffrey Craig Porges Aug 18, 2022 to Mar 4, 202523
- Chief financial officerJoel Lebowitz Feb 8, 2021 to Sep 3, 202124
- Chief operating officerKenneth Patrick Lorton Feb 13, 2024 to now25
Board members and other officers (25)
- VP, Corporate ControllerTherese Marie Abrams Mar 19, 2026 to now26
- OfficerMannix Vartan Aklian May 29, 2025 to now27
- Chief Medical OfficerMargaret Dugan Aug 3, 2023 to now28
- OfficerCony D'Cruz Feb 5, 2020 to Mar 24, 202129
- OfficerJennifer Daniel Feb 5, 2020 to Apr 2, 202130
- Vice President, ControllerJenny Herman Feb 5, 2020 to now31
- OfficerJoel Lebowitz Feb 5, 2020 to Feb 18, 202132
- OfficerJorg Weiser Feb 5, 2020 to Apr 2, 202133
- OfficerKaren Akinsanya Feb 5, 2020 to now34
- OfficerKenneth Patrick Lorton Feb 5, 2020 to Aug 10, 202335
- OfficerRamy Farid Feb 5, 2020 to Sep 18, 202036
- OfficerShane Brauner Feb 5, 2020 to Mar 2, 202137
- OfficerYvonne Tran Feb 5, 2020 to Nov 23, 202038
- Board memberKralingen Bridget A. Van Mar 10, 2025 to now39
- Board memberArun Oberoi May 19, 2022 to now40
- Board memberPeter J Skrdla May 25, 2021 to now1
- Board memberGary Sender Feb 5, 2020 to now41
- Board memberMichael Lynton Feb 5, 2020 to now42
- Board memberNancy Thornberry Feb 5, 2020 to now43
- Board memberRamy Farid Feb 5, 2020 to now36
- Board memberRichard A. Friesner Feb 5, 2020 to now44
- Board memberRosana Kapeller-Libermann Feb 5, 2020 to now45
- Board memberGary L. Ginsberg May 4, 2020 to now46
- Board memberJeffrey Chodakewitz May 4, 2020 to now47
- General counselYvonne Tran Feb 23, 2021 to now48
Products and brands
Schrödinger's computational platforms evaluate compounds in silico, with experimental accuracy on properties such as binding affinity and solubility. The company's products include molecular modeling programs in life science, and Materials Science, and an Enterprise Informatics Platform named LiveDesign, which is intended to facilitate communication among interdisciplinary research teams.
Small Molecular Discovery
Structure Prediction & Target Enablement
Hit Discovery
Hit-to-Lead & Lead Optimization
Read the full text
Drug Formulation
Biologics Discovery
Antibody Design
Peptide Discovery
Enzyme Engineering
Material Science Applications
Organic Electronics
Polymeric Materials
Consumer Packaged Goods
Catalysis & Reactivity
Thin Film Processing Energy Capture & Storage
Pharmaceutical Formulations & Delivery
Metals, Alloys & Ceramics
In addition to computational platforms, Schrödinger develops custom software for enterprises, as well as training, computer-cluster design and implementation, and research-based drug discovery projects.
Schrödinger software licenses are available to academic institutions for education and not-for-profit research.
From Wikipedia’s article on Schrödinger, Inc., shared under CC BY-SA 4.0.8
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Reo Discovery Limited Ireland9
- Schrodinger Korea LLC South Korea9
- Schrödinger GmbH Germany9
- Schrödinger India Private Limited India9
- Schrödinger Technologies Ltd United Kingdom9
- Schrödinger, KK Japan9
- Schrödinger, LLC Delaware9
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Aug 5, 20268-K Results of operations49
- Jun 29, 20268-K Regulation FD disclosure50
- Jun 23, 20268-K Executive or director change; Shareholder vote51
- Jun 8, 20268-K Executive or director change52
- May 20, 20268-K Executive or director change; Regulation FD disclosure53
- May 5, 20268-K Results of operations54
- Mar 12, 20268-K Executive or director change55
- Feb 25, 20268-K Results of operations56
- Nov 5, 20258-K Results of operations57
- Sep 8, 20258-K Executive or director change58
- Aug 6, 20258-K Results of operations59
- Jun 18, 20258-K Shareholder vote60
- Mar 2, 2021New chief executive Ramy Farid becomes CEO20
- 1990Founded Founded1
Calendar
Coming up
- Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.45) a share, on Nov 5, 2025.61
When it reported results
- Aug 5, 2026Reported quarterly or annual results49
- May 5, 2026Reported quarterly or annual results54
- Feb 25, 2026Reported quarterly or annual results56
- Nov 5, 2025Reported quarterly or annual results57
- Aug 6, 2025Reported quarterly or annual results59
- May 7, 2025Reported quarterly or annual results62
- Feb 26, 2025Reported quarterly or annual results63
- Nov 12, 2024Reported quarterly or annual results64
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
288 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 44 major events, 135 insider forms, 21 large holders, 68 other. The latest 20:
- Sep 21, 20264 EDGAR
- Sep 17, 2026144 EDGAR
- Aug 5, 2026S-8 EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Jul 17, 20264 EDGAR
- Jul 16, 2026144 EDGAR
- Jul 1, 2026144 EDGAR
- Jun 29, 20264 EDGAR
- Jun 29, 20268-K EDGAR
- Jun 23, 20264 EDGAR
- Jun 23, 20264 EDGAR
- Jun 23, 20264 EDGAR
- Jun 23, 20264 EDGAR
- Jun 23, 20264 EDGAR
- Jun 23, 20264 EDGAR
- Jun 23, 20264 EDGAR
- Jun 23, 20264 EDGAR
- Jun 23, 20268-K EDGAR
- Jun 23, 20264 EDGAR
The 288 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
45 open-market trades by officers, directors and large owners since October 2021: 0 buys and 45 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Akinsanya KarenSee Remarks | Sale | 31,599 | $29.37 | $928.0K | Form 4 |
| Jul 16, 2026 | Jain RachitEVP & CFO | Sale | 875 | $15.60 | $13.7K | Form 4 |
| Apr 17, 2026 | Farid RamyPresident & CEO | Sale | 43,000 | $12.21 | $525.0K | Form 4 |
| Apr 16, 2026 | Jain RachitEVP & CFO | Sale | 844 | $12.75 | $10.8K | Form 4 |
| Apr 16, 2026 | Farid RamyPresident & CEO | Sale | 43,000 | $12.33 | $530.2K | Form 4 |
| Mar 6, 2026 | Herman JennyCAO | Sale | 608 | $12.84 | $7.8K | Form 4 |
| Mar 5, 2026 | Jain RachitEVP & CFO | Sale | 1,631 | $12.90 | $21.0K | Form 4 |
| Mar 5, 2026 | Herman JennyCAO | Sale | 775 | $12.85 | $10.0K | Form 4 |
| Mar 5, 2026 | Tran YvonneEVP, CLO & CPO | Sale | 1,094 | $12.90 | $14.1K | Form 4 |
| Mar 5, 2026 | Lorton Kenneth PatrickEVP, CTO & COO, Software | Sale | 1,222 | $12.90 | $15.8K | Form 4 |
| Mar 5, 2026 | Farid RamyPresident & CEO | Sale | 3,661 | $12.91 | $47.3K | Form 4 |
| Mar 5, 2026 | Akinsanya KarenSee Remarks | Sale | 1,366 | $12.90 | $17.6K | Form 4 |
| Mar 4, 2026 | Abel Robert LorneSee Remarks | Sale | 1,300 | $12.81 | $16.7K | Form 4 |
| Mar 2, 2026 | Farid RamyPresident & CEO | Sale | 5,560 | $11.90 | $66.2K | Form 4 |
| Mar 2, 2026 | Akinsanya KarenSee Remarks | Sale | 2,206 | $11.99 | $26.4K | Form 4 |
| Feb 10, 2026 | Herman JennyCAO | Sale | 752 | $13.79 | $10.4K | Form 4 |
| Feb 10, 2026 | Tran YvonneEVP, CLO & CPO | Sale | 776 | $13.80 | $10.7K | Form 4 |
| Feb 10, 2026 | Lorton Kenneth PatrickEVP, CTO & COO, Software | Sale | 925 | $13.73 | $12.7K | Form 4 |
| Feb 9, 2026 | Abel Robert LorneSee Remarks | Sale | 1,230 | $13.51 | $16.6K | Form 4 |
| Oct 16, 2025 | Dugan MargaretChief Medical Officer | Sale | 1,395 | $21.07 | $29.4K | Form 4 |
All 45 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Rubric Capital Management LPSCHEDULE 13G/A, 4 filings Nov 13, 2024 to May 15, 202665
- Sumitomo Mitsui Trust GroupSCHEDULE 13G/A, 3 filings Feb 4, 2025 to Apr 30, 202666
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 202667
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 27, 202668
- BlackRockSCHEDULE 13G/A, 6 filings Feb 4, 2022 to Jul 18, 202569
- ARK Investment Management LLCSC 13G, 1 filing Feb 10, 202370
- David E. ShawSC 13G/A, 1 filing Dec 1, 202171
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Ramy FaridPresident and Chief Executive Officer | $730.0K | $4.1M72 | |
| 2025 | Karen AkinsanyaPresident, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | $600.0K | $2.1M72 | |
| 2025 | Geoffrey PorgesChief Financial Officer | $317.7K | $2.0M72 | |
| 2025 | Mannix AklianChief Commercial Officer, Global Head of Software Sales & Marketing | $286.7K | $2.0M72 | |
| 2025 | Yvonne TranChief Legal Officer and Chief People Officer | $584.0K | $1.8M72 | |
| 2025 | Richie JainChief Financial Officer | $503.7K | $1.8M72 | |
| 2024 | Ramy FaridPresident and Chief Executive Officer | $704.1K | $4.4M72 | |
| 2024 | Karen AkinsanyaPresident, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | $562.6K | $2.7M72 | |
| 2024 | Geoffrey PorgesChief Financial Officer | $627.1K | $2.4M72 | |
| 2023 | Ramy FaridPresident and Chief Executive Officer | $677.0K | $3.1M72 | |
| 2023 | Karen AkinsanyaPresident, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | $541.0K | $1.7M72 | |
| 2023 | Geoffrey PorgesChief Financial Officer | $603.0K | $1.7M72 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Schrödinger is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSchrodinger, Inc.2
- CIK0001490978
- Employer ID (EIN)95-428454119
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company19
- Incorporated inDelaware19
- Fiscal year endsDecember 312
- Industry code (SIC)2834 Pharmaceutical Preparations2
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
- Business address1540 Broadway, 24Th Floor, New York, NY 100362
- Phone503-299-11502
- Shares outstanding64,660,908 Common Stock shares; 9,164,193 Limited Common Stock shares as of Feb 18, 202619
- Public float$1.1B as of Jun 30, 202519
- AuditorKPMG LLP, Portland, OR PCAOB ID 185; it also attests to the company’s internal control over financial reporting19
- On EDGAR sinceMay 5, 20102
- Filings537 in all: 4 (289), 8-K (56), 144 (40), 3 (31), 10-Q (20), DEFA14A (10), S-8 (9), SC 13G/A (9)2
All 35 form types
SC 13G (8), 10-K (7), SCHEDULE 13G/A (7), CORRESP (6), DEF 14A (6), ARS (4), D (4), UPLOAD (4), 424B4 (2), DRS (2), EFFECT (2), S-1 (2), S-1MEF (2), S-3ASR (2), SCHEDULE 13G (2), SEC STAFF LETTER (2), 4/A (1), 424B5 (1), 5 (1), 8-A12B (1), 8-K/A (1), CERT (1), D/A (1), DRS/A (1), DRSLTR (1), PRE 14A (1), S-1/A (1)
- Latest filingsAnnual report (10-K) Feb 25, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 28, 2026
Latest 8-K (8-K) Aug 5, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, par value $0.01 per share | SDGR | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 25, 2026 (Section 12(b) of the Exchange Act).19
Risk factors and legal proceedings
The risks Schrödinger names in Item 1A of its 10-K filed Feb 25, 2026: 73 risks under these headings, as written.19
- Risks Related to Our Financial Position and Need for Additional Capital
- We have a history of significant operating losses, and we expect to incur losses over the next several years.
- If we are unable to increase sales of our software, increase revenue from our drug discovery collaborations, or if we and our current and future collaborators are unable to successfully develop and commercialize drug products, our revenues may be insufficient for us to achieve or maintain profitability.
- Our quarterly and annual results may fluctuate significantly, which could adversely impact the value of our common stock.
- We will likely require additional capital to fund our operations. If we are unable to raise additional capital on terms acceptable to us or at all or generate cash flows necessary to maintain or expand our operations, we may not be able to compete successfully, which would harm our business, operations, and financial condition.
- Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or drug programs.
- If our estimates, judgments or assumptions relating to our critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, our results of operations could be adversely affected.
- Risks Related to Our Software
- If our existing customers do not renew their licenses, do not buy additional solutions from us, or renew at lower prices, our business and operating results will suffer.
- Our software sales cycle can vary and be long and unpredictable.
- A significant portion of our revenues are generated by sales to life sciences industry customers, and factors that adversely affect this industry could adversely affect our software sales.
- The markets in which we participate are highly competitive, and if we do not compete effectively, our business and operating results could be adversely affected.
The other 63 risks
- We have invested and expect to continue to invest in research and development efforts that further enhance our computational platform. Such investments may affect our operating results, and, if the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer.
- If we are unable to collect receivables from our customers, our operating results may be adversely affected.
- Defects or disruptions in our solutions could result in diminishing demand for our solutions, a reduction in our revenues, and subject us to substantial liability.
- We rely upon third-party providers of cloud-based infrastructure to host our software solutions. Any disruption in the operations of these third-party providers, limitations on capacity, or interference with our use could adversely affect our business, financial condition, and results of operations.
- If our security measures are breached or unauthorized access to customer data is otherwise obtained, our solutions may be perceived as not being secure, customers may reduce the use of or stop using our solutions, and we may incur significant liabilities.
- Any failure to offer high-quality technical support services could adversely affect our relationships with our customers and our operating results.
- Our solutions utilize third-party open-source software, and any failure to comply with the terms of one or more of these open-source software licenses could adversely affect our business or our ability to sell our software solutions, subject us to litigation, or create potential liability.
- Risks Related to Drug Discovery
- We may never realize a return on our investment of resources and cash in our drug discovery collaborations.
- We may not realize returns on our equity investments in our drug discovery collaborators.
- Our drug discovery collaborators have significant discretion in determining when to make announcements, if any, about the status of our collaborations, including about clinical developments and timelines for advancing collaborative programs, and the price of our common stock may decline as a result of announcements of unexpected results or developments.
- Although we believe that our computational platform has the potential to identify more promising molecules than traditional methods and to accelerate drug discovery, our focus on using our platform technology to discover and design molecules with therapeutic potential may not result in the discovery and development of commercially viable products for us or our collaborators.
- We may not be successful in our efforts to identify, discover or develop product candidates and may fail to capitalize on programs, collaborations, or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.
- We rely on contract research organizations to synthesize any molecules with therapeutic potential that we discover. If such organizations do not meet our supply requirements, or if such organizations do not otherwise perform satisfactorily, development of any product candidate we may develop may be delayed.
- If we are not able to establish or maintain collaborations to develop and commercialize any of the product candidates we discover internally, we may have to alter our development and commercialization plans for those product candidates and our business could be adversely affected.
- As a company, we have very limited experience in clinical development, which may adversely impact the likelihood that we will be successful in advancing our programs.
- Conducting successful clinical trials requires the enrollment of a sufficient number of patients, and suitable patients may be difficult to identify and recruit.
- We rely on, and plan to continue to rely on, third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay our ability to seek or obtain marketing approval for or commercialize our product candidates or otherwise harm our business.
- Our reliance on third parties to manufacture our product candidates increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
- If serious adverse or unacceptable side effects are identified during the development or commercialization of our product candidates, we may need to abandon or limit our development and/or commercialization efforts for such product candidates.
- The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities.
- Interim, initial, "topline", and preliminary data from our clinical trials that we announce or publish in the future may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- We conduct, and we intend to continue to conduct, clinical trials for our product candidates at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.
- If we and any current or future collaborators are unable to successfully complete clinical development, obtain regulatory approval for, or commercialize any product candidates, or experience delays in doing so, our business may be materially harmed.
- Even if any product candidate that we may develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success.
- Clinical trial and product liability lawsuits against us could divert our resources, could cause us to incur substantial liabilities and could limit commercialization of our product candidates.
- We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, thus rendering our products non-competitive, obsolete or reducing the size of our market.
- Risks Related to Our Operations
- Doing business internationally creates operational and financial risks for our business.
- If we fail to manage our technical operations infrastructure, our existing customers, and our internal drug discovery team, may experience service outages, and our new customers may experience delays in the deployment of our solutions.
- Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition.
- Our ability to use our NOLs and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.
- Our international operations subject us to potentially adverse tax consequences.
- Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use, value added, or similar taxes, and we could be subject to tax liabilities with respect to past or future sales, which could adversely affect our results of operations.
- Unanticipated changes in our effective tax rate could harm our future results.
- We have acquired, and we may again in the future acquire, companies, businesses, solutions or technologies, which could divert our management’s attention, result in additional dilution to our stockholders, and otherwise disrupt our operations and adversely affect our operating results.
- Our operations may be interrupted by the occurrence of a natural disaster or other catastrophic event at our primary facilities.
- Risks Related to Our Intellectual Property
- If we fail to comply with our obligations under our existing license agreements with Columbia University, under any of our other intellectual property licenses, or under any future intellectual property licenses, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.
- Our obligations under our existing or future drug discovery collaboration agreements may limit our intellectual property rights that are important to our business. Further, if we fail to comply with our obligations under our existing or future collaboration agreements, or otherwise experience disruptions to our business relationships with our prior, current, or future collaborators, we could lose intellectual property rights that are important to our business.
- If we are unable to obtain, maintain, enforce, and protect patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.
- Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
- Obtaining and maintaining our patent protection depends on compliance with various deadlines and procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these deadlines and requirements. We may miss a filing deadline for patent protection on these inventions.
- Intellectual property rights do not guarantee commercial success of current or future product candidates or other business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.
- We, our prior, existing, or future collaborators, and our existing or future licensors, may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.
- Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
- We may be subject to claims by third parties asserting that our employees, consultants, or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.
- If our product candidates or any of our future product candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such products, which may result in a material decline in sales of our competing products.
- Risks Related to Regulatory and Other Legal Compliance Matters
- Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we will obtain marketing approval to commercialize a product candidate.
- Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we may develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.
- We have and may continue to seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations in the United States, and PRIME Designation in the European Union, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.
- We may not be able to obtain orphan drug exclusivity for any product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.
- Even if we, or any collaborators we may have, obtain marketing approvals for any product candidates we may develop, the terms of approvals and ongoing regulation of our products could require the substantial expenditure of resources and may limit how we, or they, manufacture and market such products, which could materially impair our ability to generate revenue.
- Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns and other developments could hinder our ability to obtain guidance from the FDA regarding our programs and develop and secure approval of our product candidates in a timely manner, which would negatively impact our business.
- Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for any of our product candidates that do receive marketing approval.
- The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed, as well as impact our ability to find collaborators for our drug discovery programs on commercially acceptable terms.
- Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition, or results of operations.
- We, and the collaborators who use our computational platform, may be subject to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations. Failure to comply with such laws and regulations, may result in substantial penalties.
- We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws, and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, be precluded from developing, manufacturing, and selling certain products outside the United States or be required to develop and implement costly compliance programs, which could adversely affect our business, results of operations and financial condition.
- Changes in and uncertainty surrounding U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.
- Our employees, independent contractors, consultants, and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading laws, which could cause significant liability for us and harm our reputation.
- Our internal information technology systems, or those of our third-party vendors, contractors, or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of
- our services, compromise sensitive information related to our business, or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.
- Climate change-related risks and uncertainties and legal or regulatory responses to climate change could negatively impact our business, financial condition, results of operations, prospects and reputation.
- Risks Related to Employee Matters and Managing Growth
- Our future success depends on our ability to retain key executives and to attract, retain, and motivate qualified personnel.
Legal proceedings
From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any material legal proceedings.
The opening of Item 3, Legal Proceedings.19
Links
- Websitewww.schrodinger.com1
- WikipediaSchrödinger, Inc.
- WikidataQ7432923
- SEC EDGARCIK 1490978
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataSchrödinger on Wikidata
- 2SEC EDGARSchrödinger filings on SEC EDGAR
- 3WikipediaSchrödinger on Wikipedia
- 4
- 5Company websiteSchrödinger logo
- 6SEC EDGARSchrödinger 10-K for fiscal 2025
- 7SEC EDGARSchrödinger filings on SEC EDGAR
- 8
- 9
- 10SEC EDGARSchrödinger 10-K for fiscal 2019
- 11SEC EDGARSchrödinger 10-K for fiscal 2021
- 12SEC EDGARSchrödinger 10-K for fiscal 2022
- 13SEC EDGARSchrödinger 10-K for fiscal 2020
- 14SEC EDGARSchrödinger 10-Q for fiscal 2025
- 15SEC EDGARSchrödinger 10-Q for fiscal 2025
- 16SEC EDGARSchrödinger 10-Q for fiscal 2026
- 17SEC EDGARSchrödinger 10-K for fiscal 2019
- 18SEC EDGARSchrödinger 10-Q for fiscal 2025
- 19
- 20SEC EDGARRamy Farid, Chief executive officer
- 21SEC EDGARKaren Akinsanya, President
- 22SEC EDGARRachit Jain, Chief financial officer
- 23
- 24
- 25
- 26
- 27SEC EDGARMannix Vartan Aklian, Officer
- 28
- 29SEC EDGARCony D'Cruz, Officer
- 30SEC EDGARJennifer Daniel, Officer
- 31
- 32SEC EDGARJoel Lebowitz, Officer
- 33SEC EDGARJorg Weiser, Officer
- 34SEC EDGARKaren Akinsanya, Officer
- 35SEC EDGARKenneth Patrick Lorton, Officer
- 36SEC EDGARRamy Farid, Officer
- 37SEC EDGARShane Brauner, Officer
- 38SEC EDGARYvonne Tran, Officer
- 39
- 40SEC EDGARArun Oberoi, Board member
- 41SEC EDGARGary Sender, Board member
- 42SEC EDGARMichael Lynton, Board member
- 43SEC EDGARNancy Thornberry, Board member
- 44SEC EDGARRichard A. Friesner, Board member
- 45
- 46SEC EDGARGary L. Ginsberg, Board member
- 47SEC EDGARJeffrey Chodakewitz, Board member
- 48SEC EDGARYvonne Tran, General counsel
- 49SEC EDGARResults of operations
- 50SEC EDGARRegulation FD disclosure
- 51
- 52SEC EDGARExecutive or director change
- 53
- 54SEC EDGARResults of operations
- 55SEC EDGARExecutive or director change
- 56SEC EDGARResults of operations
- 57SEC EDGARResults of operations
- 58SEC EDGARExecutive or director change
- 59SEC EDGARResults of operations
- 60SEC EDGARShareholder vote
- 61NasdaqNasdaq calendar
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72